Latest issue 07 Sep 2026

CRC Research Update — September 07, 2026

Today's colorectal cancer research highlights

2 min read

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

TRIAL DATA
COMMIT trial analysis examines chemoimmunotherapy in dMMR metastatic CRC
A new analysis explores what the COMMIT trial can and cannot tell us about combining chemotherapy with immunotherapy in patients with deficient DNA mismatch repair metastatic colorectal cancer. (Journal of Clinical Oncology)
RESEARCH
Tracking ctDNA after surgery identifies high-risk patients despite negative MRD status
A longitudinal study of 124 stage II-III patients found that analyzing circulating tumor DNA (ctDNA) trajectories after surgery can identify subgroups at high risk for recurrence or metastasis, even when initial minimal residual disease testing is negative. (J Gastrointest Oncol)
RESEARCH
Meta-analysis finds conflicting evidence on ctDNA RAS testing for anti-EGFR therapy
A systematic review of patients with tissue RAS wild-type tumors receiving first-line chemotherapy plus anti-EGFR therapy found inconsistent results on whether ctDNA RAS status predicts outcomes, possibly due to differences in assay sensitivity and tumor heterogeneity. (J Gastrointest Oncol)
LIVING WITH CRC
Dietary and metabolic risk factors drive rising early-onset CRC rates in the U.S.
A 33-year analysis of Global Burden of Disease data shows that while traditional colorectal cancer rates in older adults have declined, early-onset cases (diagnosed under age 50) are rising, likely driven by shifting exposures to dietary and metabolic risk factors. (J Gastrointest Oncol)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

Hospitalization outcomes differ between early- and late-onset CRC patients
A national database study (2016-2020) compared hospitalization trends and outcomes in patients diagnosed before age 50 versus those 50 and older, finding distinct patterns in mortality, length of stay, and associations with obesity and sociodemographic factors. (J Gastrointest Oncol)

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

Fruquintinib plus immunotherapy evaluated in MSS refractory mCRC
A retrospective study of 145 patients with microsatellite-stable metastatic CRC who had progressed after at least two systemic treatment lines aimed to evaluate whether fruquintinib alone, fruquintinib plus a PD-1 inhibitor, or the combination with radiotherapy improve outcomes in patients who typically derive little benefit from immunotherapy alone. (J Gastrointest Oncol)

Research continues to refine how we detect, treat, and understand colorectal cancer across all stages and subtypes.

Get CRC research intelligence delivered weekly — free.

Browse by Topic

KRAS Mutations Immunotherapy (MSI-H)BRAF Early-Onset / Under 50 Liver Metastases Clinical Trials Living with CRC All Issues

CRC Research Update

Subscribe to The CRC Digest